A Phase 2b Study in Subjects With Alcoholic Hepatitis to Evaluate Safety and Efficacy of DUR-928 Treatment

Condition:   Alcoholic Hepatitis Interventions:   Drug: DUR-928 30 mg;   Drug: DUR-928 90 mg;   Drug: Placebo+ Standard of Care (SOC) Sponsors:   Durect;   CTI Clinical Trial and Consulting Services Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials